Abstract
Biotechnology Law ReportVol. 42, No. 3 The Holman ReportRecent Developments in FDA Regulatory ExclusivitiesBy CHRISTOPHER M. HOLMANBy CHRISTOPHER M. HOLMANChristopher M. Holman is a Professor of Law at the University of Missouri-Kansas City School of Law; a Senior Scholar at the Center for the Protection of Intellectual Property at the Antonin Scalia Law School, George Mason University; and the Executive Editor of Biotechnology Law Report.Search for more papers by this authorPublished Online:9 Jun 2023https://doi.org/10.1089/blr.2023.29314.cmhAboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 42Issue 3Jun 2023 InformationCopyright 2023, Mary Ann Liebert, Inc., publishersTo cite this article:By CHRISTOPHER M. HOLMAN.Recent Developments in FDA Regulatory Exclusivities.Biotechnology Law Report.Jun 2023.118-131.http://doi.org/10.1089/blr.2023.29314.cmhPublished in Volume: 42 Issue 3: June 9, 2023Online Ahead of Print:May 26, 2023PDF download
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
